Early studies revealed that a cell-penetrating ARF inhibitory peptide effectively blocked FOXM1 activity in cultured cancer cells and mice [60,135], but the pharmacokinetics of such peptides are not suitable for clinical use. Here, CDKN2A is linked to cancer.